Targeting anticancer drugs to tumor vasculature using cationic liposomes

Pharmaceutical Research

Volumn 27, Issue 7, 2010, Pages 1171-1183

  Abu Lila, Amr S ^a   Ishida, Tatsuhiro ^a   Kiwada, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Angiogenesis; Anti angiogenic therapy; Anticancer drugs; Dosing schedule; Dual targeting; PEG coated cationic liposome; Vascular targeting

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DOXORUBICIN; DRUG CARRIER; ETOPOSIDE; GEMCITABINE; LIPOSOME; MACROGOL; OXALIPLATIN; PACLITAXEL; CATION;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD VESSEL; BREAST CANCER; CANCER CELL; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DOSAGE SCHEDULE COMPARISON; DRUG CLEARANCE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; ENCAPSULATION; ENDOTHELIUM CELL; FIBROSARCOMA; GROWTH INHIBITION; HUMAN; IMMUNE RESPONSE; LEWIS CARCINOMA; LIPOSOMAL DELIVERY; LOW DRUG DOSE; MELANOMA; MOUTH CARCINOMA; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; TARGET CELL DESTRUCTION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VASCULARIZATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULARIZATION;

ANTINEOPLASTIC AGENTS; CATIONS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77953609568     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0110-1     Document Type: Review

References (105)

1. AV Kalra RB Campbell 2006 Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting Pharm Res 23 2809 2817 1:CAS:528:DC%2BD28Xht1Kmt7zP 17066329
2. F Pastorino C Brignole D Marimpietri M Cilli C Gambini D Ribatti, et al. 2003 Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy Cancer Res 63 7400 7409 1:CAS:528:DC%2BD3sXovVGltLg%3D 14612539
3. RK Jain 2005 Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 58 62 1:CAS:528:DC%2BD2MXnvFar 15637262
4. G Bergersand LE Benjamin 2003 Tumorigenesis and the angiogenic switch Nat Rev Cancer 3 401 410
5. AW Griffioen AF Barendsz-Janson KH Mayo HF Hillen 1998 Angiogenesis, a target for tumor therapy J Lab Clin Med 132 363 368 1:CAS:528:DyaK1cXns1Oht70%3D 9823929
6. A Pezzolo F Parodi MV Corrias R Cinti C Gambini V Pistoia 2007 Tumor origin of endothelial cells in human neuroblastoma J Clin Oncol 25 376 383 1:CAS:528:DC%2BD2sXisFykur8%3D 17264333
7. CR Dassand PF Choong 2006 Targeting of small molecule anticancer drugs to the tumour and its vasculature using cationic liposomes: lessons from gene therapy Cancer Cell Int 6 17
8. X Wang Y Wang X Chen J Wang X Zhang Q Zhang 2009 NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells J Control Release 139 56 62 1:CAS:528:DC%2BD1MXhtVGrtb3F 19470394
9. T Asai S Miyazawa N Maeda K Hatanaka Y Katanasaka K Shimizu, et al. 2008 Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol- shielded liposomal DPP-CNDAC Cancer Sci 99 1029 1033 1:CAS:528: DC%2BD1cXlslCrt7o%3D 18294280
10. Y Liuand A Deisseroth 2006 Tumor vascular targeting therapy with viral vectors Blood 107 3027 3033
11. K Shimizuand N Oku 2004 Cancer anti-angiogenic therapy Biol Pharm Bull 27 599 605
12. J Ye Y Li T Hamasaki N Nakamichi T Komatsu T Kashiwagi, et al. 2008 Inhibitory effect of electrolyzed reduced water on tumor angiogenesis Biol Pharm Bull 31 19 26 1:CAS:528:DC%2BD1cXmtlaltbw%3D 18175936
13. N Ferrara 2004 Vascular endothelial growth factor as a target for anticancer therapy Oncologist 9 Suppl 1 2 10 1:CAS:528:DC%2BD2cXlsFOjurs%3D 15178810
14. RS Kerbel 2000 Tumor angiogenesis: past, present and the near future Carcinogenesis 21 505 515 1:CAS:528:DC%2BD3cXitVeit7w%3D 10688871
15. CA Staton SM Stribbling S Tazzyman R Hughes NJ Brown CE Lewis 2004 Current methods for assaying angiogenesis in vitro and in vivo Int J Exp Pathol 85 233 248 1:CAS:528:DC%2BD2cXpsFSqtLs%3D 15379956
16. S Hussain M Slevin S Matou N Ahmed MI Choudhary R Ranjit, et al. 2008 Anti-angiogenic activity of sesterterpenes; natural product inhibitors of FGF-2-induced angiogenesis Angiogenesis 11 245 256 1:CAS:528: DC%2BD1cXpsVCgtbc%3D 18330714
17. LS Rosen 2002 Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers Cancer Control 9 36 44 11965229
18. T Shibusa N Shijubo S Abe 1998 Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma Clin Cancer Res 4 1483 1487 1:STN:280:DyaK1c3ovFOlug%3D%3D 9626466
19. J Folkman 1985 Tumor angiogenesis Adv Cancer Res 43 175 203 1:STN:280:DyaL2M7psFGqsA%3D%3D 2581424
20. A Gileadand M Neeman 1999 Dynamic remodeling of the vascular bed precedes tumor growth: MLS ovarian carcinoma spheroids implanted in nude mice Neoplasia 1 226 230
21. N Qayum RJ Muschel JH Im L Balathasan CJ Koch S Patel, et al. 2009 Tumor vascular changes mediated by inhibition of oncogenic signaling Cancer Res 69 6347 6354 1:CAS:528:DC%2BD1MXpt1Cgu7w%3D 19622766
22. Z Kan K Ivancev A Lunderquist PA McCuskey RS McCuskey S Wallace 1995 In vivo microscopy of hepatic metastases: dynamic observation of tumor cell invasion and interaction with Kupffer cells Hepatology 21 487 494 1:STN:280:DyaK2M7ks1Smtw%3D%3D 7843723
23. H Hashizume P Baluk S Morikawa JW McLean G Thurston S Roberge, et al. 2000 Openings between defective endothelial cells explain tumor vessel leakiness Am J Pathol 156 1363 1380 1:STN:280:DC%2BD3c3hs1Kntg%3D%3D 10751361
24. DC Drummond O Meyer K Hong DB Kirpotin D Papahadjopoulos 1999 Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors Pharmacol Rev 51 691 743 1:CAS:528:DC%2BD3cXnslChsLg%3D 10581328
25. H Maeda J Wu T Sawa Y Matsumura K Hori 2000 Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J Control Release 65 271 284 1:CAS:528:DC%2BD3cXhtl2qsLo%3D 10699287
26. Y Matsumuraand H Maeda 1986 A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res 46 6387 6392
27. RV Iozzoand JD San Antonio 2001 Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena J Clin Invest 108 349 355
28. S Ranand PE Thorpe 2002 Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy Int J Radiat Oncol Biol Phys 54 1479 1484
29. CY Fears CL Gladson A Woods 2006 Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells J Biol Chem 281 14533 14536 1:CAS:528:DC%2BD28XkslGqsr0%3D 16574663
30. DJ Chaplin 2003 Drug based approaches for targeting tumor vasculature: development of combretastatin A4 phosphate Pathophysiol Haemost Thromb 33 Suppl 1 9 10 12954990
31. PL Felgner TR Gadek M Holm R Roman HW Chan M Wenz, et al. 1987 Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure Proc Natl Acad Sci USA 84 7413 7417 1:CAS:528:DyaL1cXjtlSgug%3D%3D 2823261
32. X Gaoand L Huang 1995 Cationic liposome-mediated gene transfer Gene Ther 2 710 722
33. PL Felgnerand GM Ringold 1989 Cationic liposome-mediated transfection Nature 337 387 388
34. T Serikawa N Suzuki H Kikuchi K Tanaka T Kitagawa 2000 A new cationic liposome for efficient gene delivery with serum into cultured human cells: a quantitative analysis using two independent fluorescent probes Biochim Biophys Acta 1467 419 430 1:CAS:528:DC%2BD3cXlvV2ltL8%3D 11030599
35. GD Schmidt-Wolfand IG Schmidt-Wolf 2003 Non-viral and hybrid vectors in human gene therapy: an update Trends Mol Med 9 67 72
36. D Niculescu-Duvaz J Heyes CJ Springer 2003 Structure-activity relationship in cationic lipid mediated gene transfection Curr Med Chem. 10 1233 1261 1:CAS:528:DC%2BD3sXksFSit7k%3D 12678797
37. M Bessodes C Dubertret G Jaslin D Scherman 2000 Synthesis and biological properties of new glycosidic cationic lipids for DNA delivery Bioorg Med Chem Lett 10 1393 1395 1:CAS:528:DC%2BD3cXksFygt7k%3D 10890172
38. M Sainlos M Hauchecorne N Oudrhiri S Zertal-Zidani A Aissaoui JP Vigneron, et al. 2005 Kanamycin A-derived cationic lipids as vectors for gene transfection Chembiochem 6 1023 1033 1:CAS:528:DC%2BD2MXlsVSqtbw%3D 15883979
39. R Leventisand JR Silvius 1990 Interactions of mammalian cells with lipid dispersions containing novel metabolizable cationic amphiphiles Biochim Biophys Acta 1023 124 132
40. E Khazanov D Simberg Y Barenholz 2006 Lipoplexes prepared from cationic liposomes and mammalian DNA induce CpG-independent, direct cytotoxic effects in cell cultures and in mice J Gene Med 8 998 1007 1:CAS:528:DC%2BD28XpsFKis78%3D 16741997
41. P Pinnaduwage L Schmitt L Huang 1989 Use of a quaternary ammonium detergent in liposome mediated DNA transfection of mouse L-cells Biochim Biophys Acta 985 33 37 1:CAS:528:DyaK3cXkt1egug%3D%3D 2790044
42. S Li WC Tseng DB Stolz SP Wu SC Watkins L Huang 1999 Dynamic changes in the characteristics of cationic lipidic vectors after exposure to mouse serum: implications for intravenous lipofection Gene Ther 6 585 594 1:CAS:528:DyaK1MXit1Olsrs%3D 10476218
43. D Simberg S Weisman Y Talmon A Faerman T Shoshani Y Barenholz 2003 The role of organ vascularization and lipoplex-serum initial contact in intravenous murine lipofection J Biol Chem 278 39858 39865 1:CAS:528:DC%2BD3sXnvFamsr8%3D 12869564
44. BD Freimark HP Blezinger VJ Florack JL Nordstrom SD Long DS Deshpande, et al. 1998 Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes J Immunol 160 4580 4586 1:CAS:528:DyaK1cXjtVCqs7g%3D 9574565
45. S Dokka D Toledo X Shi V Castranova Y Rojanasakul 2000 Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes Pharm Res 17 521 525 1:CAS:528:DC%2BD3cXksVGqtbc%3D 10888302
46. O Zelphati LS Uyechi LG Barron FC Szoka Jr 1998 Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells Biochim Biophys Acta 1390 119 133 1:CAS:528:DyaK1cXht1WisLs%3D 9507083
47. S Varsano I Frolkis D Ophir 1995 Expression and distribution of cell-membrane complement regulatory glycoproteins along the human respiratory tract Am J Respir Crit Care Med 152 1087 1093 1:STN:280:DyaK2Mzpt1ymsQ%3D%3D 7545058
48. S Simoes A Filipe H Faneca M Mano N Penacho N Duzgunes, et al. 2005 Cationic liposomes for gene delivery Expert Opin Drug Deliv 2 237 254 1:CAS:528:DC%2BD2MXjsFantr8%3D 16296751
49. P Pires S Simoes S Nir R Gaspar N Duzgunes MC Pedroso de Lima 1999 Interaction of cationic liposomes and their DNA complexes with monocytic leukemia cells Biochim Biophys Acta 1418 71 84 1:CAS:528:DyaK1MXjtVWgu7k%3D 10209212
50. NJ Caplen E Kinrade F Sorgi X Gao D Gruenert D Geddes, et al. 1995 In vitro liposome-mediated DNA transfection of epithelial cell lines using the cationic liposome DC-Chol/DOPE Gene Ther 2 603 613 1:CAS:528:DyaK2MXptVCmurk%3D 8548549
51. A Abu-Lila T Suzuki Y Doi T Ishida H Kiwada 2009 Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model J Control Release 134 18 25 1:CAS:528: DC%2BD1MXhsFeltrc%3D 19010364
52. SH Jung H Seong SH Cho KS Jeong BC Shin 2009 Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity Int J Pharm 382 254 261 1:CAS:528:DC%2BD1MXhtlSlur7I 19666094
53. AS Abu Lila T Ishida H Kiwada 2009 Recent advances in tumor vasculature targeting using liposomal drug delivery systems Expert Opin Drug Deliv 6 1297 1309 1:CAS:528:DC%2BD1MXhs1aqtLfI 19780711
54. Y Takakura M Nishikawa F Yamashita M Hashida 2002 Influence of physicochemical properties on pharmacokinetics of non-viral vectors for gene delivery J Drug Target 10 99 104 1:CAS:528:DC%2BD38XivV2it78%3D 12074546
55. VP Torchilin 1998 Polymer-coated long-circulating microparticulate pharmaceuticals J Microencapsul 15 1 19 1:CAS:528:DyaK1cXhs1KlsL8%3D 9463803
56. C Allen N Dos Santos R Gallagher GN Chiu Y Shu WM Li, et al. 2002 Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol) Biosci Rep 22 225 250 1:CAS:528:DC%2BD38Xpt1emsbo%3D 12428902
57. D Papahadjopoulos TM Allen A Gabizon E Mayhew K Matthay SK Huang, et al. 1991 Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy Proc Natl Acad Sci USA 88 11460 11464 1:CAS:528:DyaK38XmslWjsg%3D%3D 1763060
58. MC Woodleand DD Lasic 1992 Sterically stabilized liposomes Biochim Biophys Acta 1113 171 199
59. TS Levchenko R Rammohan AN Lukyanov KR Whiteman VP Torchilin 2002 Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating Int J Pharm 240 95 102 1:CAS:528: DC%2BD38Xktlaru7o%3D 12062505
60. RB Campbell B Ying GM Kuesters R Hemphill 2009 Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics J Pharm Sci 98 411 429 1:CAS:528:DC%2BD1MXhs1Kmtr4%3D 18563780
61. RB Campbell D Fukumura EB Brown LM Mazzola Y Izumi RK Jain, et al. 2002 Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors Cancer Res 62 6831 6836 1:CAS:528:DC%2BD38XpsVahs78%3D 12460895
62. S Krasnici A Werner ME Eichhorn M Schmitt-Sody SA Pahernik B Sauer, et al. 2003 Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels Int J Cancer 105 561 567 1:CAS:528:DC%2BD3sXktlOqsbk%3D 12712451
63. T Nomura N Koreeda F Yamashita Y Takakura M Hashida 1998 Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors Pharm Res 15 128 132 1:CAS:528: DyaK1cXosFSjug%3D%3D 9487559
64. AS Abu Lila S Kizuki Y Doi T Suzuki T Ishida H Kiwada 2009 Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model J Control Release 137 8 14 1:CAS:528:DC%2BD1MXmvVKqsLc%3D 19285528
65. JH Senior 1987 Fate and behavior of liposomes in vivo: a review of controlling factors Crit Rev Ther Drug Carrier Syst 3 123 193 1:CAS:528:DyaL2sXptVSitw%3D%3D 3542245
66. JH Senior KR Trimble R Maskiewicz 1991 Interaction of positively-charged liposomes with blood: implications for their application in vivo Biochim Biophys Acta 1070 173 179 1:CAS:528:DyaK38XmslSgsw%3D%3D 1751523
67. S Zalipsky E Brandeis MS Newman MC Woodle 1994 Long circulating, cationic liposomes containing amino-PEG-phosphatidylethanolamine FEBS Lett 353 71 74 1:CAS:528:DyaK2cXmvVKnu7w%3D 7926026
68. DC Litzinger JM Brown I Wala SA Kaufman GY Van CL Farrell, et al. 1996 Fate of cationic liposomes and their complex with oligonucleotide in vivo Biochim Biophys Acta 1281 139 149 8664312
69. H Ishiwata N Suzuki S Ando H Kikuchi T Kitagawa 2000 Characteristics and biodistribution of cationic liposomes and their DNA complexes J Control Release 69 139 148 1:CAS:528:DC%2BD3cXmvFOrsrc%3D 11018552
70. DD Stuart GY Kao TM Allen 2000 A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1 Cancer Gene Ther 7 466 475 1:CAS:528:DC%2BD3cXisV2hs7w%3D 10766353
71. AS Abu Lila Y Doi K Nakamura T Ishida H Kiwada 2010 Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor J Control Release 142 167 173 1:CAS:528:DC%2BC3cXhvFehur8%3D 19861140
72. YS Chang E di Tomaso DM McDonald R Jones RK Jain LL Munn 2000 Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood Proc Natl Acad Sci USA 97 14608 14613 1:CAS:528:DC%2BD3MXitVGitw%3D%3D 11121063
73. G Thurston JW McLean M Rizen P Baluk A Haskell TJ Murphy, et al. 1998 Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice J Clin Invest 101 1401 1413 1:CAS:528:DyaK1cXitleksLs%3D 9525983
74. S Sengupta P Tyagi T Velpandian YK Gupta SK Gupta 2000 Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies Pharmacol Res 42 459 464 1:CAS:528: DC%2BD3cXntFWqsbo%3D 11023708
75. R Kunstfeld G Wickenhauser U Michaelis M Teifel W Umek K Naujoks, et al. 2003 Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model J Invest Dermatol 120 476 482 1:CAS:528:DC%2BD3sXitlOhtL0%3D 12603862
76. S Strieth ME Eichhorn B Sauer B Schulze M Teifel U Michaelis, et al. 2004 Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature Int J Cancer 110 117 124 1:CAS:528:DC%2BD2cXjtlKqsbk%3D 15054876
77. M Schmitt-Sody S Strieth S Krasnici B Sauer B Schulze M Teifel, et al. 2003 Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy Clin Cancer Res 9 2335 2341 1:CAS:528:DC%2BD3sXksVajs70%3D 12796403
78. ME Eichhorn S Luedemann S Strieth A Papyan H Ruhstorfer H Haas, et al. 2007 Cationic lipid complexed camptothecin (EndoTAG-2) improves antitumoral efficacy by tumor vascular targeting Cancer Biol Ther 6 920 929 1:CAS:528:DC%2BD2sXht1yktrnF 17534143
79. J Wu A Lee Y Lu RJ Lee 2007 Vascular targeting of doxorubicin using cationic liposomes Int J Pharm 337 329 335 1:CAS:528:DC%2BD2sXlsFagsL8%3D 17275230
80. ME Eichhorn I Ischenko S Luedemann S Strieth A Papyan A Werner, et al. 2010 Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer Int J Cancer 126 1235 1245 1:CAS:528:DC%2BC3cXjsFeg 19697323
81. E Pasquier S Honore B Pourroy MA Jordan M Lehmann C Briand, et al. 2005 Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells Cancer Res 65 2433 2440 1:CAS:528:DC%2BD2MXisFGnsL4%3D 15781659
82. BA Teicher EA Sotomayor ZD Huang 1992 Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease Cancer Res 52 6702 6704 1:CAS:528:DyaK3sXjt1Gnug%3D%3D 1384969
83. M Kohandel M Kardar M Milosevic S Sivaloganathan 2007 Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies Phys Med Biol 52 3665 3677 1:CAS:528:DC%2BD2sXoslGls78%3D 17664569
84. PA Burkeand SJ DeNardo 2001 Antiangiogenic agents and their promising potential in combined therapy Crit Rev Oncol Hematol 39 155 171
85. S Ghoshand P Maity 2007 Augmented antitumor effects of combination therapy with VEGF antibody and cisplatin on murine B16F10 melanoma cells Int Immunopharmacol 7 1598 1608
86. JJ Knox D Hedley A Oza R Feld LL Siu E Chen, et al. 2005 Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial J Clin Oncol 23 2332 2338 1:CAS:528:DC%2BD2MXjsVyhsr0%3D 15800324
87. M Martinelli K Bonezzi E Riccardi E Kuhn R Frapolli M Zucchetti, et al. 2007 Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel Br J Cancer 97 888 894 1:CAS:528:DC%2BD2sXhtFSnurbP 17848949
88. CM Lee T Tanaka T Murai M Kondo J Kimura W Su, et al. 2002 Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo Cancer Res 62 4282 4288 1:CAS:528:DC%2BD38XlvFeltbo%3D 12154030
89. S Strieth CF Nussbaum ME Eichhorn M Fuhrmann M Teifel U Michaelis, et al. 2008 Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes Int J Cancer 122 452 460 1:CAS:528:DC%2BD2sXhsVOnsrnM 17918179
90. J Huwyler J Drewe S Krahenbuhl 2008 Tumor targeting using liposomal antineoplastic drugs Int J Nanomedicine 3 21 29 1:CAS:528:DC%2BD1cXlsV2qtLw%3D 18488413
91. X Qi Z Chu YY Mahller KF Stringer DP Witte TP Cripe 2009 Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein Clin Cancer Res 15 5840 5851 1:CAS:528:DC%2BD1MXhtFars73E 19737950
92. H Hillaireauand P Couvreur 2009 Nanocarriers' entry into the cell: relevance to drug delivery Cell Mol Life Sci 66 2873 2896
93. KJ Longmuir SM Haynes JL Baratta N Kasabwalla RT Robertson 2009 Liposomal delivery of doxorubicin to hepatocytes in vivo by targeting heparan sulfate Int J Pharm 382 222 233 1:CAS:528:DC%2BD1MXhtlSlur7M 19664697
94. F Pastorino C Brignole D Di Paolo B Nico A Pezzolo D Marimpietri, et al. 2006 Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy Cancer Res 66 10073 10082 1:CAS:528:DC%2BD28XhtVyiur7K 17047071
95. G Schulz DA Cheresh NM Varki A Yu LK Staffileno RA Reisfeld 1984 Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients Cancer Res 44 5914 5920 1:STN:280:DyaL2M%2FkvVOkuw%3D%3D 6498849
96. G Schuch 2005 EndoTAG-1. MediGene Curr Opin Investig Drugs 6 1259 1265 1:CAS:528:DC%2BD28Xjs1Wruw%3D%3D 16370392
97. Ridwelski K, Kettner E, Fahlke J, Bartelheim K, Hitzl M, Schulze B, et al. Phase I study of the anti-neovascular agent MBT-0206 to evaluate safety and efficacy in patients with metastatic or advanced unresectable gastrointestinal cancer (GI cancer). J Clin Oncol ASCO annual meeting proceedings (post meeting edition). 22: Abs 3163 (2004).
98. Bartelheim K, Ognerubov NA, Semiglazov VF, Vtoraya OM, Kaletta C, Reichenberger I, et al. Phase Ib study of the anti-neovascular agent MBT-0206 to evaluate safety and efficacy in patients with metastatic breast cancer. J Clin Oncol ASCO annual meeting proceedings (post meeting edition). 22: Abs 3079 (2004).
99. M Loehr S Haas W Bechstein M Karrasch A Mescheder I Meyer, et al. 2008 First-line treatment of inoperable pancreatic adenocarcinoma with lipid complexed paclitaxel nanoparticles plus gemcitabine compared with gemcitabine monotherapy. A prospective RCT - phase II study J Clin Oncol 26 4618
100. M Loehr G Bodoky U Fölsch A Marten M Karrasch C Lilla, et al. 2009 Cationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer: a phase II trial J Clin Oncol 27 4526
101. J Denekampand B Hobson 1982 Endothelial-cell proliferation in experimental tumours Br J Cancer 46 711 720
102. J Denekamp 1984 Vascular endothelium as the vulnerable element in tumours Acta Radiol Oncol 23 217 225 1:STN:280:DyaL2M%2FktlWgtA%3D%3D 6208746
103. RK Jain 1998 The next frontier of molecular medicine: delivery of therapeutics Nat Med 4 655 657 1:CAS:528:DyaK1cXjsFygsLg%3D 9623964
104. X Huang G Molema S King L Watkins TS Edgington PE Thorpe 1997 Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature Science 275 547 550 1:CAS:528:DyaK2sXnvVCkuw%3D%3D 8999802
105. ME Eichhorn S Becker S Strieth A Werner B Sauer M Teifel, et al. 2006 Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging Cancer Biol Ther 5 89 96 1:CAS:528: DC%2BD28XkvVSnt7s%3D 16357513